Purpose: We quantified the rates of over and under diagnosis of prostate cancer in 2 large patient cohorts during the last 15 years.

Materials And Methods: A total of 2,126 men with clinical stage T1c prostate cancer were treated with radical prostatectomy during 1 of the 3 periods 1989 to 1995, 1995 to 2001 and 2001 to 2005. The respective proportions of men with a tumor that met our criteria for over diagnosis (0.5 cm3 or less, confined to the prostate with clear surgical margins and no Gleason pattern 4 or 5) and under diagnosis (nonorgan confined, pathological stage T3 or greater, or positive surgical margins) were examined.

Results: The proportion of men with an over diagnosed tumor was 1.3% to 7.1%. The proportion with prostate cancer that was under diagnosed was 25% to 30%. An ancillary finding was that decreasing the prostate specific antigen threshold for biopsy from 4.0 to 2.5 ng/ml in the screened population resulted in a lower rate of under diagnosis from 30% to 26%, a higher rate of over diagnosis from 1.3% to 7.1% and an increase in the 5-year progression-free survival rate from 85% to 92%. Men who were 55 years or younger were significantly more likely to meet our criteria for over diagnosed cancer.

Conclusions: Under diagnosis of prostate cancer continues to occur more frequently than over diagnosis. Lowering the prostate specific antigen threshold for recommending biopsy to 2.5 ng/ml resulted in a lower rate of under diagnosis and a higher progression-free survival rate.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2007.03.017DOI Listing

Publication Analysis

Top Keywords

prostate cancer
20
diagnosis prostate
12
rate diagnosis
12
diagnosis
9
prostate
8
surgical margins
8
13% 71%
8
prostate specific
8
specific antigen
8
antigen threshold
8

Similar Publications

Prognostic factors for overall survival in castration-resistant metastatic prostate cancer treated with docetaxel (MeProCSS): results from a German real-world cohort.

Int Urol Nephrol

January 2025

Department of Urology and Urosurgery, Medical Faculty Mannheim, University Medical Centre Mannheim (UMM), University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Baden-Württemberg, Germany.

Purpose: To identify prognostic factors for overall survival (OS) and develop a prognostic score in patients receiving docetaxel in metastatic castration-resistant prostate cancer (mCRPC).

Methods: Retrospective analysis was conducted on mCRPC patients treated with docetaxel at a German tertiary center between March 2010 and November 2023. Prognostic clinical and laboratory factors were analyzed using uni- and multivariable logistic regression.

View Article and Find Full Text PDF

Purpose: The study explores the role of multimodal imaging techniques, such as [F]F-PSMA-1007 PET/CT and multiparametric MRI (mpMRI), in predicting the ISUP (International Society of Urological Pathology) grading of prostate cancer. The goal is to enhance diagnostic accuracy and improve clinical decision-making by integrating these advanced imaging modalities with clinical variables. In particular, the study investigates the application of few-shot learning to address the challenge of limited data in prostate cancer imaging, which is often a common issue in medical research.

View Article and Find Full Text PDF

Background: Active surveillance (AS) is the guideline-recommended treatment for low-risk prostate cancer and involves routine provider visits, lab tests, imaging, and prostate biopsies. Despite good uptake, adherence to AS, in terms of receiving recommended follow-up testing and remaining on AS in the absence of evidence of cancer progression, remains challenging.

Objective: We sought to better understand urologist, primary care providers (PCPs), and patient experiences with AS care delivery to identify opportunities to improve adherence.

View Article and Find Full Text PDF

Objectives: To develop and validate a lesion-based grading system using clinicopathological and MRI features for predicting positive surgical margin (PSM) following robotic-assisted laparoscopic prostatectomy (RALP) among prostate cancer (PCa) patients.

Methods: Consecutive MRI examinations of patients undergoing RALP for PCa were retrospectively collected from two medical institutions. Patients from center 1 undergoing RALP between January 2020 and December 2021 were included in the derivation cohort and those between January 2022 and December 2022 were allocated to the validation cohort.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!